Scholar Rock Holding (SRRK) Earnings Call Presentation

Positive Ph2 EMBRAZE Trial Demonstrating Preservation of Lean Mass with Highly Selective Anti-Myostatin Inhibitor During Tirzepatide-Induced Weight Loss June 18, 2025 © 2025 Scholar Rock, Inc. All rights reserved. Today's Speakers David L. Hallal Chief Executive Officer Akshay Vaishnaw, M.D., Ph.D. President, Research & Development © 2025 Scholar Rock, Inc. All rights reserved. 2 Agenda | TOPIC | SPEAKER | | --- | --- | | Scholar Rock's Leading | David L. Hallal | | Anti-Myostatin Platform | Chief Executive ...